Primary Peritoneal Carcinoma Completed Phase 2 Trials for Irinotecan (DB00762)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01091259Irinotecan and Bevacizumab for Recurrent Ovarian CancerTreatment